| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 27,545 | 27,545 |
| Impact on cash from foreign currency translation | -196 | -188 |
| Net increase (decrease) in cash and cash equivalents | 6,812 | 12,452 |
| Cash and cash equivalents at beginning of period | 20,922 | - |
| Cash and cash equivalents at end of period | 27,734 | - |
Inmune Bio, Inc. (INMB)
Inmune Bio, Inc. (INMB)